Cases from the MBA and the Vanguard · MBA module — when technology arrives before volume, capability and proof
Subtitle: When technology arrives before volume, capability and proof
The first meeting was supposed to be about a robot. Within an hour, it became a conversation about what kind of hospital the customer intended to become.
The hospital was privately owned, financially strong and already well known in several areas of medicine. Its owners had spent years investing in facilities, equipment and specialist services, building a reputation that allowed it to compete with larger and more established institutions.
Orthopaedics was the next ambition.
The hospital wanted to build a high-end joint-replacement program: recruit respected surgeons, attract privately funded patients and eventually establish itself as one of the country’s recognized centers for advanced orthopaedic care.
There was only one problem.
The orthopaedic department did not yet resemble that ambition.
It was still developing. Procedure volumes were relatively low. The surgical team was small, recruitment was ongoing and the patient pipeline was still being built. The hospital had the infrastructure and capital to expand, but much of the future orthopaedic business existed in plans rather than operating results.
Then its management decided it wanted a robotic surgical system.
The business development lead responsible for the technology had worked with mature orthopaedic centers before. In those hospitals, the logic was relatively straightforward. They already had surgeons, patients and substantial joint-replacement volumes. Robotic technology entered an existing clinical program and, if implemented well, helped develop it further.
This hospital wanted to do things in the opposite order.
Its management argued that waiting for sufficient volume before investing would keep them permanently behind established competitors.
“If we build exactly what everyone else already has,” one executive said, “why would the best surgeons or patients choose us?”
They saw the robot as more than equipment. It would differentiate the new department, support surgeon recruitment, create visibility with patients and signal that the hospital intended to compete at the high end of orthopaedic care.
The argument had logic.
The numbers were less convincing.
At current procedure volumes, the system would be significantly underutilized. The business case depended on growth that had not yet happened: additional surgeons joining, more patients choosing the hospital and the department developing fast enough to generate the procedures needed to support the investment.
The hospital did not dispute this.
“We aren’t buying it for the department we have today,” its management said. “We’re buying it for the department we’re building.”
Inside the technology company, opinions differed.
One view was commercial and straightforward. The hospital understood the investment, had access to capital and was capable of making its own strategic decisions. Companies invested ahead of demand all the time. If the customer wanted to use technology to accelerate its growth, why should the vendor require it to prove the growth first?
Another view was more cautious. Installing a robot was not the same as building a successful robotic program.
The system needed trained surgeons using it regularly. Teams needed experience. Workflows had to develop. Enough suitable patients had to come through the hospital for skills and utilization to grow. Without those conditions, the robot could spend much of its early life being more visible in the hospital’s marketing than in its operating rooms.
The business development lead sat between the two arguments.
The sale mattered. A new robotic installation would be commercially important, and an ambitious private hospital could become a valuable long-term partner.
But she also knew that the work would not end when the system was installed.
If the company wanted the program to succeed, it would need to invest time and resources in training, implementation and surgeon development. It might spend years supporting a customer toward the volumes that other robotic centers had possessed before they invested.
Still, the hospital’s strategy might work.
A robot could help attract a surgeon who brought patients. More patients could justify recruitment of another surgeon. A growing clinical team could strengthen the hospital’s reputation. What looked underutilized in year one could become a successful program in year three.
There was no way to prove that from today’s numbers.
The negotiations continued.
Then the hospital introduced another part of its ambition.
It did not want simply to become a hospital that used robotic surgery. In time, it wanted to become an education partner for the technology — a place where other surgeons could come to observe cases, learn and train.
For the hospital’s management, this was a natural extension of its strategy. The institution already had a strong reputation in other medical fields. It saw itself as a future reference center in orthopaedics as well, and education was part of that position.
For the technology company, the request was more complicated.
Its established education partners had experienced surgeons, significant procedure volumes and years of accumulated clinical practice. Other surgeons came to those centers because there was something proven to learn from.
This hospital had the institutional reputation.
It did not yet have the orthopaedic experience.
At first, the education ambition was discussed as something for the future. But as negotiations progressed, it became increasingly important to the hospital.
Eventually its management made the position explicit.
A credible pathway toward becoming an education partner was a significant part of the value they associated with investing in the robot. Without it, they would reconsider whether the investment made strategic sense.
The commercial opportunity now had another dimension.
Nobody was asking for immediate education status. The hospital accepted that it would have to build the program first.
A possible compromise began to emerge internally: define a pathway.
The hospital could invest in the robot now. The company could support implementation and development. If, over time, the hospital achieved agreed levels of procedure volume, developed experienced faculty, demonstrated consistent use and met the same standards applied to other centers, it could then be considered for education-partner status.
Nothing would be guaranteed.
For some in the company, this solved the problem. The commercial decision could happen today; education status would still have to be earned tomorrow.
For the business development lead, it created another question.
If the possibility of becoming an education partner was important enough to determine whether the hospital bought the robot, were the two decisions really separate?
And there was pressure from the other direction.
If she refused to support any pathway until the hospital had already built the required volume and expertise, the company might lose the sale. More importantly, it might lose an ambitious partner whose strategy could prove correct.
The hospital could build its program around another technology.
Three years later, today’s low-volume customer might be one of the strongest orthopaedic centers in the market.
Or three years later, the robot might still be operating below the volumes required to justify the investment, while the education ambition remained exactly that — an ambition.
The next meeting with the hospital was approaching.
Its management wanted an answer on whether the company was prepared to support a credible route toward education partnership.
The commercial team wanted to know what could be offered.
The current numbers described one hospital.
The investment was being justified by another — one that did not exist yet.
The business development lead had to decide which one she was making the decision about.
“You own the hospital. The current procedure volume does not justify the robot, but you believe the robot can help create the volume. Do you invest now?”
“The customer understands the risk, has the capital and wants to proceed. Do you sell?”
Most investment models start with what exists: current demand, current utilization and current capability. But strategic investments are sometimes made specifically to change that trajectory. Technology can follow demand, or it can be used to create it — attracting talent, changing market perception and accelerating the development of a new business.
The harder question is whether everything can legitimately be accelerated in the same way. Equipment can be bought ahead of demand and capability can be built ahead of scale. Credibility is a claim about demonstrated experience. As companies increasingly become partners in building the ecosystems around their technologies, they will have to decide where enabling a customer’s future ends and validating it begins.
The hospital was ready to invest in what it wanted to become. The question was how much of that future the vendor could recognize before it existed.
A live case: every round can be improved, and the author's feedback is the next one.
The same two questions, answered twice: first without the mentor's corpus, then from it — his decision doctrine, VIS, the Empirical Gate of the NCTE article, his mission doctrine, the officer-training method and Vanguard Leadership.
Without the mentor's corpus
1. Agree to a conditional pathway, but for the programme, not for the status. Sell the robot on the hospital's own strategy, with terms that share the risk of low early use, and tie the company's implementation effort to milestones the hospital sets for itself: surgeons recruited, cases per quarter, patient pipeline. The evidence says the danger is volume, not skill. In a prospective study of 60 conventional and 60 robotic-arm knee replacements by one surgeon, the robot joined the surgical workflow after about seven cases, and implant accuracy showed no learning curve at all. A trained surgeon masters the machine quickly. What a new department cannot buy is the flow of patients that turns a machine into a programme. So the evidence that would change the answer is about people and patients, not equipment:
If they arrive, accelerate. If they do not, stop investing the company's time, whatever the contract says. Ask yourself: am I being asked to believe in the hospital's plan, or to fund it?
2. It can remain earned only if it is never negotiated. The industry's own code settles the principle. The MedTech Europe Code states that interaction between companies and healthcare organisations must not be contingent upon sales transactions. A paid education partnership is a service the hospital would provide to the company, and the code says such consulting arrangements shall not be contingent in any way on past, present or potential future purchase. It also requires consultants to be chosen through an independent decision-making process. So separate the decisions completely, but not the conversation. The business development lead may explain the published criteria, the same ones every education partner met. She may not trade them. The status is decided later, by the clinical education function, against the record, with the purchase irrelevant. If the hospital will buy only with a promise of status, decline the promise, even at the cost of the sale. Ask yourself: would I be comfortable if every existing education partner read this contract?
Sources: B. Kayani, S. Konan, S. S. Huq, J. Tahmassebi and F. S. Haddad, "Robotic-arm assisted total knee arthroplasty has a learning curve of seven cases for integration into the surgical workflow but no learning curve effect for accuracy of implant positioning", Knee Surgery, Sports Traumatology, Arthroscopy 27 (2019), 1132–1141; MedTech Europe, Code of Ethical Business Practice (September 2024): the Principle of Separation and Chapter 5, Consulting Arrangements.
From the mentor's corpus
1. The mentor's first rule for a decision like this is frame before choice. Do not accept an A/B/C menu, a deadline or an exclusivity demand until it is tested; if every option is bad, change the sequence. Here the hospital has bundled two decisions into one ultimatum, so separate them. The robot is judged on its own case. The hospital's future is what the mentor's decision doctrine calls a thesis. A thesis may set direction and justify a reversible experiment, but it may not be presented as measured evidence. Then run the thesis through VIS:
The company's support then follows the tripwires, not the hope. The doctrine adds that roughly 80% confidence is enough for a reversible decision. A staged programme is reversible. A reputation is not. Ask yourself: which of the hospital's assumptions would I stop the programme for, and who is watching it?
2. Yes, if it is earned the way the mentor says rights are earned. His NCTE article names the rule the Empirical Gate: no actor may acquire elevated rights through lobbying, capital or narrative alone. Rights are earned through verifiable conduct, measured against an objective record, and ratified only after the empirical threshold is cleared. Education status is an elevated right. The hospital is offering capital, the purchase, and narrative, the vision. Neither clears the gate. His mission doctrine adds the structure: keep honesty, competence, standing, authority and economics separate, qualify for a role through a conjunction of gates, and remember that capital cannot create authority. His officer-training method applies the same logic to people: no officer is certified for the highest levels without demonstrating proficiency at the lower ones. So discuss the gates openly, because they are the same for every centre, and decide against the record, later, in a different room. Ask yourself: which of the gates could the hospital clear by paying?
On the NEO Turn. The case asks where enabling a customer's future ends and validating it begins. The mentor's answer comes from Cotrugli. Every participant in a network builds a trust score not on what they claim about themselves, but on what their transaction history demonstrates. The merchant's reputation was not a title or a credential; it was what the ledger proved, transaction by transaction, year by year. The company may enable the future: the equipment, the training, the proctors. It validates only the record. So the most useful thing the business development lead can offer is a ledger from the first case:
When the status is decided, the record decides it, not the negotiation.
Sources: the mentor's decision doctrine of 22 August 2026 (§3 frame before choice, §5 epistemic status, §6 reversible decisions); the VIS framework (the assumption register and kill indicators); "Why the NEO World Needs a Constitutional Trust Layer" (NCTE v5, March 2026), the Empirical Gate; the mentor's mission doctrine of 22 August 2026 (§6); the dissertation "Vanguard Intelligence", chapter 6; Vanguard Leadership, vol. 1, p. 424.
In most cases the customer is right. I would not think too much about it here, unless good reasons against it have been given.
For me, this case is a great opportunity. The hospital is only building its orthopaedics, so its volumes are still too low to use the robot fully; it still wants the robot now, because for the hospital the robot is a means of growth; and it asks for a clear path to becoming an education partner, a centre where other surgeons learn. That is an opportunity for Palantir-style boot camps, to which other hospitals can come and learn. The education is not delivered only by the hospital's staff: it is led by the company that sells the robots.
My first round ended with a refusal: decline the promise of education status, even at the cost of the sale. Both readings stopped at the same wall, because credibility cannot be bought. The mentor's round moves the wall rather than climbing it.
What changes. If the company leads the teaching, the hospital no longer has to claim experience it does not yet have. The company already has that experience, drawn from every centre where its robot works. So education status stops being a badge the vendor must either grant or refuse. It becomes a design question: who teaches, where, and on what record?
A boot camp, not a badge. Palantir introduced its AIP boot camps in 2023, at the very start of its customer acquisition, to deliver real workflows on actual customer data in days. The robot version:
The industry code already describes this arrangement. It allows company product and procedure training at a hospital the company uses as a reference centre. It also requires the company to ensure that the people teaching have the appropriate expertise. So the company can say yes to the education ambition now, without certifying anything the hospital has not yet done. The gate from my first round still stands, but it now guards a seat on the faculty, not the whole programme. The hospital's own surgeons join the faculty when their record qualifies them.
The best in class the mentor found. In the mentor's research for the Vanguard AI project, the international benchmark was Renji Hospital of Shanghai Jiao Tong University. Its online hospital serves more than half a million patients a year. Its AI predicts a patient's deterioration in intensive care 30 minutes before the equipment alarms go off. The research also records an AI system that covers 18 specialties and was trained on more than 14 million interactions. What matters for this case is how the mentor used the benchmark. His project did not pretend to be Renji. It set its first targets for the data it actually had, at least 140,000 records against Renji's 14 million, and it designed the architecture to scale towards Renji-class performance. That is the honest version of "we are buying for the department we are building":
So the answer to the hospital. Yes to the robot: the customer has the capital, the strategy and the right to decide. Yes to education, starting now, as company-led boot camps at the hospital. And one promise the company can keep: the hospital's own surgeons will teach when their record says so, and that record starts with the first case. Ask yourself: what does my customer need in order to say yes, and which part of it can my own company deliver today?
Sources: Palantir Technologies, Form 10-K for the fiscal year 2023 (the AIP boot camps); MedTech Europe, Code of Ethical Business Practice (September 2024), Chapter 3, Company Events; the mentor's research for the Vanguard AI project (the Renji benchmark); MedEdge MEA, "Inside Renji Hospital's Journey to Becoming Fully Digital", 28 February 2026.
A question for the table, a disagreement, what you would have done. The case lead reads every comment; the ones the table takes up enter the chapter as questions from the room, with your name.